Studies genetic and biologic markers linked to lung decline in pulmonary fibrosis
Compares genetic and biologic markers with symptom changes in adults with idiopathic pulmonary fibrosis.
Plain-language title generated from the registry record
Registry title: Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
Key facts
- Where
- Pittsburgh, United StatesSee the site
Where in United States
- Michelle F MacPhersonPittsburgh, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Pittsburgh
- Trial code
- NCT00373841
- Record updated
- 27 August 2026
- Original description
The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.Read full original descriptionShow less
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis
The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.
Inclusion: Patients who are 18 or older; Diagnosis of Idiopathic Pulmonary Fibrosis; Treated at the Simmons Center.
Exclusion: Other Lung Illness.